Business Description
Northwest Biotherapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US66737P6007
Description
Northwest Biotherapeutics Inc is a biotechnology company involved in the development of cancer vaccines. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S. Food and Drug Administration.
Financial Strength
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.05 | |||||
| Equity-to-Asset | -2.36 | |||||
| Debt-to-Equity | -0.69 | |||||
| Debt-to-EBITDA | -0.82 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -73.36 | |||||
| Beneish M-Score | -3.32 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 58.9 | |||||
| 3-Year EPS without NRI Growth Rate | 23.8 | |||||
| 3-Year FCF Growth Rate | 1.3 | |||||
| 3-Year Book Growth Rate | 49.6 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 56.85 | |||||
| 9-Day RSI | 46.66 | |||||
| 14-Day RSI | 43.6 | |||||
| 6-1 Month Momentum % | -40.19 | |||||
| 12-1 Month Momentum % | -1.6 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.09 | |||||
| Quick Ratio | 0.09 | |||||
| Cash Ratio | 0.05 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -12.3 | |||||
| Shareholder Yield % | -1.08 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -2873.09 | |||||
| Net Margin % | -3240.11 | |||||
| FCF Margin % | -2954.14 | |||||
| ROA % | -205.93 | |||||
| ROIC % | -93.23 | |||||
| ROC (Joel Greenblatt) % | -274.5 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 511.74 | |||||
| EV-to-EBIT | -10.58 | |||||
| EV-to-EBITDA | -10.91 | |||||
| EV-to-Revenue | 314.22 | |||||
| EV-to-FCF | -10.19 | |||||
| Earnings Yield (Greenblatt) % | -9.45 | |||||
| FCF Yield % | -9.33 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:NWBO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Northwest Biotherapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1.932 | ||
| EPS (TTM) ($) | -0.06 | ||
| Beta | -1.16 | ||
| Volatility % | 72.5 | ||
| 14-Day RSI | 43.6 | ||
| 14-Day ATR ($) | 0.034915 | ||
| 20-Day SMA ($) | 0.480072 | ||
| 12-1 Month Momentum % | -1.6 | ||
| 52-Week Range ($) | 0.4001 - 1.09 | ||
| Shares Outstanding (Mil) | 1,195.36 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Northwest Biotherapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Northwest Biotherapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Northwest Biotherapeutics Inc Frequently Asked Questions
What is Northwest Biotherapeutics Inc(NWBO)'s stock price today?
The current price of NWBO is $0.51. The 52 week high of NWBO is $1.09 and 52 week low is $0.40.
When is next earnings date of Northwest Biotherapeutics Inc(NWBO)?
The next earnings date of Northwest Biotherapeutics Inc(NWBO) is 2024-05-10 Est..
Does Northwest Biotherapeutics Inc(NWBO) pay dividends? If so, how much?
Northwest Biotherapeutics Inc(NWBO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers